DB:1KA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines to treat patients with serious and rare diseases in the United States and internationally.


Snowflake Analysis

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has Akcea Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1KA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.3%

1KA

1.7%

DE Biotechs

4.3%

DE Market


1 Year Return

-28.6%

1KA

9.3%

DE Biotechs

0.3%

DE Market

Return vs Industry: 1KA underperformed the German Biotechs industry which returned 9.3% over the past year.

Return vs Market: 1KA underperformed the German Market which returned 0.3% over the past year.


Shareholder returns

1KAIndustryMarket
7 Day2.3%1.7%4.3%
30 Day-15.0%18.5%7.4%
90 Day-10.8%15.3%-0.2%
1 Year-28.6%-28.6%9.6%9.3%2.0%0.3%
3 Yearn/a17.7%16.1%-5.0%-12.3%
5 Yearn/a19.1%16.9%4.2%-9.2%

Price Volatility Vs. Market

How volatile is Akcea Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Akcea Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1KA (€13.53) is trading below our estimate of fair value (€66.85)

Significantly Below Fair Value: 1KA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1KA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 1KA is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1KA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1KA is good value based on its PB Ratio (3x) compared to the DE Biotechs industry average (5.2x).


Next Steps

Future Growth

How is Akcea Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

58.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1KA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1KA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1KA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1KA's revenue (41.9% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: 1KA's revenue (41.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1KA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Akcea Therapeutics performed over the past 5 years?

-6.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1KA is currently unprofitable.

Growing Profit Margin: 1KA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 1KA is unprofitable, and losses have increased over the past 5 years at a rate of -6.2% per year.

Accelerating Growth: Unable to compare 1KA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1KA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).


Return on Equity

High ROE: 1KA has a negative Return on Equity (-5.74%), as it is currently unprofitable.


Next Steps

Financial Health

How is Akcea Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 1KA's short term assets ($458.9M) exceed its short term liabilities ($36.3M).

Long Term Liabilities: 1KA's short term assets ($458.9M) exceed its long term liabilities ($13.9M).


Debt to Equity History and Analysis

Debt Level: 1KA is debt free.

Reducing Debt: 1KA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 1KA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 1KA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 11.7% per year.


Next Steps

Dividend

What is Akcea Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1KA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1KA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1KA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1KA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1KA's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

Damien McDevitt (52yo)

0.67

Tenure

US$10,946,636

Compensation

Dr. Damien McDevitt, Ph.D., serves as Director of Akcea Therapeutics, Inc since October 04, 2018 and served as its Interim Chief Executive Officer since September 23, 2019 until March 25, 2020. He serves ...


CEO Compensation Analysis

Compensation vs Market: Damien's total compensation ($USD10.95M) is above average for companies of similar size in the German market ($USD1.48M).

Compensation vs Earnings: Insufficient data to compare Damien's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Damien McDevitt
CEO & Director0.67yrUS$10.95m0.015% $212.8k
Alex Howarth
Chief Operating Officer0.42yrUS$4.51mno data
Paula Soteropoulos
0.67yrUS$7.40m0.22% $3.1m
Kyle Jenne
Chief Commercial Officer3yrsUS$3.59m0.0021% $29.4k
Michael Price
Executive VP & CFOno datano datano data
Angelyn Lowe
Executive Director of Corporate Communications & Investor Relations0.083yrno datano data
Joshua Patterson
General Counsel0.17yrno data0.027% $370.3k
Carla Poulson
Senior VP & Chief Human Resources Officerno datano datano data
Jeffrey Goldberg
0.67yrUS$7.65m0.15% $2.1m
Louis St. O'Dea
Chief Medical Officer4.33yrsUS$1.66m0.017% $229.5k

0.7yrs

Average Tenure

50.5yo

Average Age

Experienced Management: 1KA's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Damien McDevitt
CEO & Director0.67yrUS$10.95m0.015% $212.8k
B. Parshall
Chairman of the Board0.42yrUS$467.25kno data
Sandford Smith
Independent Director3.17yrsUS$453.38kno data
Elaine Hochberg
Independent Director3.17yrsUS$460.71kno data
Joseph Klein
Independent Director0.67yrUS$792.56kno data
Joseph Witztum
Member of Cardio Metabolic Advisory Boardno datano datano data
Johannes Jacob Kastelein
Member of Cardio Metabolic Advisory Boardno datano datano data
Sotirios Tsimikas
Member of Cardio Metabolic Advisory Boardno datano datano data
Rosanne Crooke
Member of Cardio Metabolic Advisory Boardno datano datano data
Michael Yang
Independent Director0.67yrUS$791.28kno data

1.1yrs

Average Tenure

62yo

Average Age

Experienced Board: 1KA's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 1KA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.


Top Shareholders

Company Information

Akcea Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Akcea Therapeutics, Inc.
  • Ticker: 1KA
  • Exchange: DB
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.533b
  • Listing Market Cap: US$1.386b
  • Shares outstanding: 101.51m
  • Website: https://www.akceatx.com

Number of Employees


Location

  • Akcea Therapeutics, Inc.
  • 22 Boston Wharf Road
  • 9th Floor
  • Boston
  • Massachusetts
  • 2210
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AKCANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2017
1KADB (Deutsche Boerse AG)YesCommon StockDEEURJul 2017

Biography

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, an antisense medicine designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome, as well as is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of homozygous familial hypercholesterolemia; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/29 00:37
End of Day Share Price2020/05/28 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.